MIR-143 is involved in endothelial cell dysfunction through suppression of glycolysis and correlated with atherosclerotic plaques formation

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 19, 2016, Pages 4063-4071

  Xu, R H ^a   Liu, B ^a   Wu, J D ^a   Yan, Y Y ^a   Wang, J N ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Atherosclerotic plaque formation; Endothelial cell dysfunction; Glycolysis; MIR 143

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE; HEXOKINASE 2; LACTIC ACID; MESSENGER RNA; MICRORNA 143; OXYGEN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; MICRORNA; MIRN143 MICRORNA, HUMAN;

ADULT; AORTIC ENDOTHELIAL CELL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ATHEROSCLEROSIS; GENETICS;

ATHEROSCLEROSIS; ENDOTHELIAL CELLS; GLYCOLYSIS; HUMANS; MICRORNAS; PLAQUE, ATHEROSCLEROTIC;

EID: 85016465104     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. NOYES AM, THOMPSON PD. A systematic review of the time course of atherosclerotic plaque regression. Atherosclerosis 2014; 234: 75-84.
2. LEISCHIK R, FOSHAG P, STRAUSS M, GARG P, DWORRAK B, LITTWITZ H, LAZIC JS, HORLITZ M. Physical activity, cardiorespiratory fitness and carotid intima thickness: sedentary occupation as risk factor for atherosclerosis and obesity. Eur Rev Med Pharmacol Sci 2015; 19: 3157-3168.
3. SHANMUGAM N, ROMAN-REGO A, ONG P, KASKI JC. Atherosclerotic plaque regression: fact or fiction? Cardiovasc Drugs Ther 2010; 24: 311-317.
4. SITIA S, TOMASONI L, ATZENI F, AMBROSIO G, CORDIANO C, CATAPANO A, TRAMONTANA S, PERTICONE F, NACCARATO P, CAMICI P, PICANO E, CORTIGIANI L, BEVILACQUA M, MILAZZO L, CUSI D, BARLASSINA C, SARZI-PUTTINI P, TURIEL M. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010; 9: 830-834.
5. FUNK SD, YURDAGUL AJ, ORR AW. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med 2012; 2012: 569654.
6. DHARMASHANKAR K, WIDLANSKY ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 2010; 12: 448-455.
7. POLET F, FERON O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med 2013; 273: 156-165.
8. VERDEGEM D, MOENS S, STAPOR P, CARMELIET P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab 2014; 2: 19.
9. SUN X, FEINBERG MW. Regulation of endothelial cell metabolism: just go with the flow. Arterioscler Thromb Vasc Biol 2015; 35: 13-15.
10. DE BOCK K, GEORGIADOU M, SCHOORS S, KUCHNIO A, WONG BW, CANTELMO AR, QUAEGEBEUR A, GHESQUIERE B, CAUWENBERGHS S, EELEN G, PHNG LK, BETZ I, TEMBUYSER B, BREPOELS K, WELTI J, GEUDENS I, SEGURA I, CRUYS B, BIFARI F, DECIMO I, BLANCO R, WYNS S, VANGINDERTAEL J, ROCHA S, COLLINS RT, MUNCK S, DAELEMANS D, IMAMURA H, DEVLIEGER R, RIDER M, VAN VELDHOVEN PP, SCHUIT F, BARTRONS R, HOFKENS J, FRAISL P, TELANG S, DEBERARDINIS RJ, SCHOONJANS L, VINCKIER S, CHESNEY J, GERHARDT H, DEWERCHIN M, CARMELIET P. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 2013; 154: 651-663.
11. AMERES SL, ZAMORE PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-488.
12. CROCE CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
13. CHEN XH, LING XM, SHI S. microRNA-106a induces the proliferation and apoptosis of glioma cells through regulating JNK/MAPK pathway. Eur Rev Med Pharmacol Sci 2015; 19: 3412-3417.
14. HA M, KIM VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15: 509-524.
15. BIDZHEKOV K, GAN L, DENECKE B, ROSTALSKY A, HRISTOV M, KOEPPEL TA, ZERNECKE A, WEBER C. microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. Thromb Haemost 2012; 107: 619-625.
16. PATRA KC, WANG Q, BHASKAR PT, MILLER L, WANG Z, WHEATON W, CHANDEL N, LAAKSO M, MULLER WJ, ALLEN EL, JHA AK, SMOLEN GA, CLASQUIN MF, ROBEY RB, HAY N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-228.
17. ALLISON SJ, KNIGHT JR, GRANCHI C, RANI R, MINUTOLO F, MILNER J, PHILLIPS RM. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis 2014; 3: e102.
18. WONG N, OJO D, YAN J, TANG D. PKM2 contributes to cancer metabolism. Cancer Lett 2015; 356: 184-191.
19. GROSCHNER LN, WALDECK-WEIERMAIR M, MALLI R, GRAIER WF. Endothelial mitochondria-less respiration, more integration. Pflugers Arch 2012; 464: 63-76.
20. FANG R, XIAO T, FANG Z, SUN Y, LI F, GAO Y, FENG Y, LI L, WANG Y, LIU X, CHEN H, LIU XY, JI H. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 2012; 287: 23227-23235.
21. PESCHIAROLI A, GIACOBBE A, FORMOSA A, MARKERT EK, BONGIORNO-BORBONE L, LEVINE AJ, CANDI E, D'ALESSANDRO A, ZOLLA L, FINAZZI AA, MELINO G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013; 32: 797-802.
22. JIANG S, ZHANG LF, ZHANG HW, HU S, LU MH, LIANG S, LI B, LI Y, LI D, WANG ED, LIU MF. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. Embo J 2012; 31: 1985-1998.